Merrill Lynch maintains Human Genome at neutral

Human Genome Sciences, Inc. was maintained by Merrill Lynch analyst Hari Sambasivam at a neutral rating after the company disclosed positive Albuferon data from its phase 2 study at a medical conference that shows efficacy and lack of safety issues to date, along with positive clinician feedback. Positive details from its phase 2 study for Lymphostat-B in rheumatoid arthritis also were presented at the conference, along with phase 1 data from two trials for HGS-ETR-1 that show no drug interaction with chemotherapy when treating patients with solid malignancies. Shares of the Rockville, Md., biopharmaceutical company were down 21 cents, or 2.19%, at $9.36 on volume of 2,894,440 shares versus the three-month running average of 3,574,190 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.